Walter & Keenan Financial Consulting Co. MI ADV raised its position in shares of Merck & Company, Inc. (NYSE:MRK) by 2.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 40,870 shares of the company’s stock after buying an additional 1,000 shares during the period. Merck & Company comprises approximately 1.4% of Walter & Keenan Financial Consulting Co. MI ADV’s investment portfolio, making the stock its 21st largest position. Walter & Keenan Financial Consulting Co. MI ADV’s holdings in Merck & Company were worth $2,551,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Solaris Asset Management LLC raised its position in Merck & Company by 3.8% in the third quarter. Solaris Asset Management LLC now owns 1,635 shares of the company’s stock worth $102,000 after buying an additional 60 shares during the period. Acrospire Investment Management LLC raised its position in Merck & Company by 5.9% in the second quarter. Acrospire Investment Management LLC now owns 1,800 shares of the company’s stock worth $104,000 after buying an additional 100 shares during the period. Roble Belko & Company Inc raised its position in Merck & Company by 124.7% in the second quarter. Roble Belko & Company Inc now owns 1,802 shares of the company’s stock worth $104,000 after buying an additional 1,000 shares during the period. NewSquare Capital LLC raised its position in Merck & Company by 14.2% in the second quarter. NewSquare Capital LLC now owns 2,104 shares of the company’s stock worth $121,000 after buying an additional 261 shares during the period. Finally, Pinkerton Retirement Specialists LLC raised its position in Merck & Company by 1,925.2% in the second quarter. Pinkerton Retirement Specialists LLC now owns 2,248 shares of the company’s stock worth $130,000 after buying an additional 2,137 shares during the period. Institutional investors and hedge funds own 72.43% of the company’s stock.

Institutional Ownership by Quarter for Merck & Company (NYSE:MRK)

Shares of Merck & Company, Inc. (NYSE:MRK) traded up 0.18% during trading on Friday, hitting $62.32. 6,424,183 shares of the company traded hands. The company has a market capitalization of $171.82 billion, a price-to-earnings ratio of 31.83 and a beta of 0.77. The company has a 50 day moving average price of $60.73 and a 200 day moving average price of $61.13. Merck & Company, Inc. has a 52 week low of $47.97 and a 52 week high of $65.46.

Merck & Company (NYSE:MRK) last released its earnings results on Tuesday, October 25th. The company reported $1.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.08. The firm earned $10.50 billion during the quarter, compared to analyst estimates of $10.17 billion. Merck & Company had a net margin of 13.76% and a return on equity of 24.25%. The business’s revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the business earned $0.96 EPS. On average, analysts expect that Merck & Company, Inc. will post $3.79 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Monday, January 9th. Stockholders of record on Thursday, December 15th were issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 3.02%. The ex-dividend date of this dividend was Tuesday, December 13th. This is a positive change from Merck & Company’s previous quarterly dividend of $0.46. Merck & Company’s dividend payout ratio (DPR) is 95.92%.

ILLEGAL ACTIVITY NOTICE: “Walter & Keenan Financial Consulting Co. MI ADV Acquires 1,000 Shares of Merck & Company, Inc. (MRK)” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The original version of this piece can be accessed at http://www.dailypolitical.com/2017/01/13/walter-keenan-financial-consulting-co-mi-adv-acquires-1000-shares-of-merck-company-inc-mrk.html.

A number of research analysts have recently commented on MRK shares. Vetr lowered shares of Merck & Company from a “buy” rating to a “hold” rating and set a $64.84 price target for the company. in a research report on Monday, October 10th. Barclays PLC restated an “overweight” rating on shares of Merck & Company in a research report on Wednesday, October 12th. Leerink Swann restated a “market perform” rating and set a $65.00 price target on shares of Merck & Company in a research report on Wednesday, October 12th. Bank of America upgraded shares of Merck & Company from a “neutral” rating to a “buy” rating and upped their target price for the stock from $57.00 to $70.00 in a research report on Thursday, October 13th. Finally, Zacks Investment Research upgraded shares of Merck & Company from a “hold” rating to a “buy” rating and set a $70.00 target price for the company in a research report on Friday, October 14th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $65.79.

In related news, EVP Julie L. Gerberding sold 85,523 shares of Merck & Company stock in a transaction dated Monday, November 7th. The shares were sold at an average price of $60.02, for a total transaction of $5,133,090.46. Following the completion of the sale, the executive vice president now owns 77,762 shares in the company, valued at approximately $4,667,275.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman Kenneth C. Frazier sold 140,000 shares of Merck & Company stock in a transaction dated Thursday, November 10th. The shares were sold at an average price of $65.03, for a total transaction of $9,104,200.00. Following the sale, the chairman now owns 514,957 shares of the company’s stock, valued at approximately $33,487,653.71. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by insiders.

Merck & Company Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

5 Day Chart for NYSE:MRK

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.